Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
about
Society of Gynecologic Oncology recommendations for the prevention of ovarian cancerSalpingectomy as a means to reduce ovarian cancer riskMajor clinical research advances in gynecologic cancer in 2015Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.Malignant Brenner tumor associated with a germline BRCA2 mutation.Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.An overview of hereditary breast and ovarian cancer syndrome.The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.Genome-wide association study of breast cancer in the Japanese population.Hormonal therapy and risk of breast cancer in mexican women.In their own words: treating very young BRCA1/2 mutation-positive women with care and caution.Hormonal contraception--what kind, when, and for whom?Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersThe Angelina Jolie Effect in Jewish Law: Prophylactic Mastectomy and Oophorectomy in BRCA CarriersRisk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.Establishing a program for individuals at high risk for breast cancer.Preventive care and evaluation of the adolescent with a breast mass.Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testingGenetic risk and gynecologic cancers.Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registryReproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry.Management of genetic syndromes predisposing to gynecologic cancers.Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods.Cancer risk management decision making for BRCA+ women.Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.Options in Prophylactic Surgery to Prevent Ovarian Cancer in High-Risk Women: How New Hypotheses of Fallopian Tube Origin Influence Recommendations.Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Family Communication, Risk Perception and Cancer Knowledge of Young Adults from BRCA1/2 Families: a Systematic Review.Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.Ovarian Cancer Prevention in High-risk Women.Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.BRCA mutations in the manifestation and treatment of ovarian cancer.Assessing the Role of Reversible Contraceptives in the Health Care of Women as it Pertains to Cancer Prevention.Therapeutic, prophylactic, untoward, and contraceptive effects of combined oral contraceptives: catholic teaching, natural law, and the principle of double effect when deciding to prescribe and use.Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2.Ovarian cancer: diagnosis and treatment.
P2860
Q27009306-7281A6E9-B03D-4580-9286-25C512ED45A3Q27011949-445EBCC2-D8C7-4333-84DC-4D1FEF359AAEQ28077183-328577D8-6CE6-4E30-B168-4B050B3C7A6AQ30370475-873B6784-21DA-4B51-976B-4176FA7B7EDAQ33763270-1B264D67-6328-455D-A7E5-8AA80C7C96B6Q33845209-9F54550F-E440-42DA-85E6-39A0580DE939Q34216239-CA2DA1C8-58E2-493C-8581-1DDC1368C841Q34305000-C18229AF-AED3-49FC-B516-FC79DAF4A236Q35018746-AC6E60FF-756F-4955-878A-A9FBB5EEC1E8Q35021642-5084C5CA-664B-46C4-A360-70DE4BACD7C5Q35048651-85D23992-9063-41CA-B010-4364B307BF73Q35105959-D05BD7B9-C968-4BA4-8C9A-3F140747D04FQ35144750-F316629C-3693-46F1-A303-97E73C0C5F83Q35687632-FD8EE564-100D-479C-B481-72D92A8D30D4Q35690548-7256CD6F-B0F4-4FA8-826B-FFDA7A2F7D9DQ35925255-9ACF765A-DE6B-4244-8D34-7E6F35D13F6FQ36218446-FB195C96-71D0-43D0-865A-1DAA9C80E805Q36313479-2BE50C35-B554-42B9-8567-A2E87C116704Q36983389-D601B0BD-3ADA-4AFC-95C4-1E502479D556Q36996080-86496D3A-7E76-40D6-BB02-6183E50698BEQ37055268-0EFB3489-0CC4-44A6-B797-1AD6D8518E3EQ37468316-6B2B686D-AB0F-407F-B84C-B458E8D3F45EQ37594378-A1941D9E-9724-4379-937E-71CD307C1CBAQ37632099-7520510E-EBFF-45C0-9B46-A9F6C466118CQ38073703-46ADF85C-5D45-44A5-B76A-AD2381C188A8Q38242066-86238883-F407-4F0B-96FE-49586EE5F05BQ38513642-3B7C9F79-63FA-4CED-8983-BF81C744EF13Q38564191-57B52F77-F92A-4B44-A2F4-EBEEBDE804F5Q38711217-EEDB29A9-C272-4A93-8B15-5201A36D2D9AQ38794773-23F58B88-183A-440C-993B-F5DD79D06785Q38979257-AA221E11-C847-4B89-8CA0-6892A504F313Q39408271-C787428B-0BAB-4D4C-9B2E-EF130B6E47BCQ44256039-F97408BC-E98A-4C36-B2EB-DEB3C73DE852Q45068704-2211EE4E-0406-4229-BA9B-70016FF704B1Q46109910-5FAACB3B-80C3-42D2-9758-CE8A3A2A92EDQ47134293-FBC80675-52E5-43C0-8D29-065DE7D1BBA2Q47612930-3A8A5A70-2DF4-49EC-A402-0C429A5C1386Q48071988-3707CD09-AFD7-4E53-AB9C-E7F07F0507D5Q51003387-74BB117C-A8B7-424B-B21E-F7798C6D0098Q54942320-DC47F7CF-5977-43C9-B423-21C7474778F2
P2860
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oral contraceptive use and bre ...... 1/2 carriers: a meta-analysis.
@ast
Oral contraceptive use and bre ...... 1/2 carriers: a meta-analysis.
@en
Oral contraceptive use and bre ...... 1/2 carriers: a meta-analysis.
@nl
type
label
Oral contraceptive use and bre ...... 1/2 carriers: a meta-analysis.
@ast
Oral contraceptive use and bre ...... 1/2 carriers: a meta-analysis.
@en
Oral contraceptive use and bre ...... 1/2 carriers: a meta-analysis.
@nl
prefLabel
Oral contraceptive use and bre ...... 1/2 carriers: a meta-analysis.
@ast
Oral contraceptive use and bre ...... 1/2 carriers: a meta-analysis.
@en
Oral contraceptive use and bre ...... 1/2 carriers: a meta-analysis.
@nl
P2093
P50
P1476
Oral contraceptive use and bre ...... 1/2 carriers: a meta-analysis.
@en
P2093
P304
P356
10.1016/J.EJCA.2010.04.018
P577
2010-05-27T00:00:00Z